Search
Displaying 451–460 of 929 results for “vision connection”
-
Kriya Therapeutics Licenses Emerging Foundation-Funded Dry AMD Gene Therapy
Research NewsThe Foundation Fighting Blindness is funding Bärb Rohrer, PhD, Medical University of South Carolina, to evaluate safety and efficacy of the gene therapy in a large animal model
-
Ocugen to Launch Clinical Trial for Cross-Cutting RP Gene Therapy
Research NewsThe clinical trial is for RHO and NR2E3 mutations, but the retinal gene therapy has the potential to benefit people with a variety of other mutated genes
-
Telling His Story of Resilience
Beacon StoriesChad has been working in the corporate world for the last 20 years. But after becoming the first blind executive to graduate from the Harvard Business School leadership program, he realized his purpose in life is to help others by sharing the lessons he learned while losing his eyesight. He can now add published author to his repertoire with his new book, Blind Ambition.
-
The Beauty in Embracing Yourself
Beacon StoriesAward-nominated recording artist Lachi has collaborated with some of the biggest names in the industry with millions of streams on her music. But with all her many amazing musical accomplishments, it wasn’t until a few years ago that she fully embraced herself as a legally blind artist who identifies with the disability community as closely as she does with music.
-
Biogen’s Phase 2/3 Clinical Trial for XLRP Gene Therapy Doesn’t Meet Primary Endpoint
Research NewsMore details from the clinical trial will be reported at a later date
-
Foundation Fighting Blindness and Usher 1F Collaborative to Launch Natural History Study
Foundation NewsThe project will help identify outcome measures for future clinical trials of potential USH1F therapies.
-
ProQR’s RNA Therapy for USH2A Performs Well in Phase 1/2 Clinical Trial
Research NewsThe company is planning two Phase 2/3 clinical trials for the treatment
-
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision
In the PressFormer Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of Luxturna™, to lead development of SparingVision’s proprietary asset, SPVN06, and further pipeline development
-
Stargazer Pharmaceuticals Initiates a Phase 2a Clinical Trial for its Stargardt Disease Drug
In the PressThe Foundation Fighting Blindness Retinal Degeneration Fund is an investor in the company
-
4D Molecular Therapeutics Launches Phase 1 Clinical Trial for Choroideremia Gene Therapy
Research NewsGene therapy delivered by intravitreal injection
.png)
.png)
